PrimeRFP SCOUT · Federal Contract Recompete Brief

36C77022N0092Pharmaceutical - abaloparatide INJ for TUCSON — Radius Health, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Mar 10, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

National Cmop Office (36C770)

Awarding office

Radius Health, Inc

Recipient

Mar 10, 2022

PoP end

$676K

Obligated

$676K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Radius Health, Inc — $90

Contract facts

Federal

Contract number36C77022N0092

Also listed as36C770-22-N-0092

Also listed as36F79718D0363-36C77022N0092

AgencyNational Cmop Office (36C770)

Awarding officeNational Cmop Office (36C770)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentRadius Health, Inc

CAGE7VA71

UEIXWM2P8FKM1Y5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79718D0363

Place of performanceBOSTON MA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startMar 8, 2022

PoP end (current)Mar 10, 2022

Obligated$676K

Current value$676K

Potential value$676K

PHARMACEUTICAL - ABALOPARATIDE INJ FOR TUCSON CMOP is a federal award for National Cmop Office (36C770) held by Radius Health, Inc. Estimated value $676K ($676K obligated). Current period of performance ends Mar 10, 2022. Last award drew 1 bidder. Place of performance: BOSTON MA.

PHARMACEUTICAL - ABALOPARATIDE INJ FOR TUCSON CMOP

Recompete timing

Public

● Past PoP end (1625 days ago)

Current PoP ended Mar 10, 2022 (1625 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C77022N0092?

36C77022N0092 (Pharmaceutical - abaloparatide INJ for TUCSON) is a National Cmop Office (36C770) award with a potential value of $676K, currently held by Radius Health, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C770-22-N-0092?

36C770-22-N-0092 is the dashed form of PIID 36C77022N0092 (Pharmaceutical - abaloparatide INJ for TUCSON), held by Radius Health, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C77022N0092?

National Cmop Office (36C770) awarded 36C77022N0092 to Radius Health, Inc (potential $676K).

Who is the incumbent on 36C77022N0092?

Radius Health, Inc is the incumbent. The current period of performance ends Mar 10, 2022.

When does Radius Health, Inc’s 36C77022N0092 come up for recompete?

SCOUT tracks a period-of-performance end of Mar 10, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Mar 8, 2022 · refreshed monthly